As has been pointed out before, Abilify has somewhat unusual pharmacodynamics in that it acts as a partial agonist of D2 receptors and it seems this is the case especially at lower dosages. This makes me wonder if the dosage could also be the key to avoid the loss of effect phenomenon.
Because of the long half-life, the effect from a decrease/increase in dosage would take quite a while to show up. Let's say Abilify stopped working a couple of weeks after the last increase of dosage, could it be that it actually stopped working because the steady-state concentration became too high for it to be effective for ME/CFS? It may be a bit of a long shot, but it seems to me like a possible hypothesis.